{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:09:46Z","timestamp":1779368986473,"version":"3.53.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s41669-026-00641-2","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:46:28Z","timestamp":1773233188000},"page":"519-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Follitropin Delta Compared with Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France"],"prefix":"10.1007","volume":"10","author":[{"given":"Samir","family":"Hamamah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Carette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Markert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"641_CR1","unstructured":"WHO | Infertility is a global public health issue. WHO n.d. http:\/\/www.who.int\/reproductivehealth\/topics\/infertility\/perspective\/en\/. Accessed 28 Jan 2021."},{"key":"641_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1177\/1559827614558020","volume":"10","author":"BV Rossi","year":"2016","unstructured":"Rossi BV, Abusief M, Missmer SA. Modifiable risk factors and infertility. Am J Lifestyle Med. 2016;10:220\u201331. https:\/\/doi.org\/10.1177\/1559827614558020.","journal-title":"Am J Lifestyle Med"},{"key":"641_CR3","unstructured":"NHS. Infertility 2017. https:\/\/www.nhs.uk\/conditions\/infertility\/. Accessed 9 Apr 2021."},{"key":"641_CR4","unstructured":"Sant\u00e9 Publique France. La fertilit\u00e9 des couples en France. Num\u00e9ro th\u00e9matique. Enjeux environnementaux pour la fertilit\u00e9 humaine n.d. \/notices\/la-fertilite-des-couples-en-france.-numero-thematique.-enjeux-environnementaux-pour-la-fertilite-humaine (accessed May 3, 2021)."},{"key":"641_CR5","first-page":"1","volume":"556","author":"\u00c9deL Rochebrochard","year":"2018","unstructured":"Rochebrochard \u00c9deL. 1 enfant sur 30 con\u00e7u par assistance m\u00e9dicale \u00e0 la procr\u00e9ation en France. Popul Soc. 2018;556:1\u20134.","journal-title":"Popul Soc"},{"key":"641_CR6","unstructured":"Inserm. Infertilit\u00e9. Des difficult\u00e9s \u00e0 concevoir d\u2019origines multiples. Inserm - Sci Pour Sant\u00e9 n.d. https:\/\/www.inserm.fr\/information-en-sante\/dossiers-information\/infertilite. Accessed 28 Jan 2021."},{"key":"641_CR7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","volume":"44","author":"A Golan","year":"1989","unstructured":"Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430\u201340. https:\/\/doi.org\/10.1097\/00006254-198906000-00004.","journal-title":"Obstet Gynecol Surv"},{"key":"641_CR8","unstructured":"European Medicines Agency (EMA). Summary of product characteristics 2023. European public assessment reports (EPAR). REKOVELLE, INN-follitropin delta. n.d."},{"key":"641_CR9","unstructured":"European Medicines Agency (EMA). Summary of product characteristics 2024. European public assessment reports (EPAR). GONAL-f, INN-follitropin alfa. n.d."},{"key":"641_CR10","unstructured":"European Medicines Agency (EMA). Summary of product characteristics 2023. European public assessment reports (EPAR). Puregon, INN-follitropin beta. n.d."},{"key":"641_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-024-01372-w","volume":"17","author":"S Palomba","year":"2024","unstructured":"Palomba S, Caserta D, Levi-Setti PE, Busnelli A. Efficacy and safety of follitropin delta for ovarian stimulation in vitro fertilization\/ intracytoplasmic sperm injection cycles: a systematic review with meta-analysis. J Ovarian Res. 2024;17:60. https:\/\/doi.org\/10.1186\/s13048-024-01372-w.","journal-title":"J Ovarian Res"},{"key":"641_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13020177","volume":"13","author":"B Doroftei","year":"2023","unstructured":"Doroftei B, Ilie O-D, Anton N, Marcu O-A, Scripcariu I-S, Ilea C. A narrative review discussing the efficiency of personalized dosing algorithm of follitropin delta for ovarian stimulation and the reproductive and clinical outcomes. Diagnostics. 2023;13:177. https:\/\/doi.org\/10.3390\/diagnostics13020177.","journal-title":"Diagnostics"},{"key":"641_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.fertnstert.2016.10.033","volume":"107","author":"A Nyboe Andersen","year":"2017","unstructured":"Nyboe Andersen A, Nelson SM, Fauser BCJM, Garc\u00eda-Velasco JA, Klein BM, Arce J-C, et al. Individualized versus conventional ovarian stimulation for in\u00a0vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107:387-396.e4. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.10.033.","journal-title":"Fertil Steril"},{"key":"641_CR14","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1093\/humrep\/deab155","volume":"36","author":"J Qiao","year":"2021","unstructured":"Qiao J, Zhang Y, Liang X, Ho T, Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF\/ICSI patients. Hum Reprod Oxf Engl. 2021;36:2452\u201362. https:\/\/doi.org\/10.1093\/humrep\/deab155.","journal-title":"Hum Reprod Oxf Engl"},{"key":"641_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.rbmo.2021.09.014","volume":"44","author":"O Ishihara","year":"2022","unstructured":"Ishihara O, Nelson SM, Arce J-C. Comparison of ovarian response to follitropin delta in Japanese and White IVF\/ICSI patients. Reprod Biomed Online. 2022;44:177\u201384. https:\/\/doi.org\/10.1016\/j.rbmo.2021.09.014.","journal-title":"Reprod Biomed Online"},{"key":"641_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.fertnstert.2024.05.143","volume":"122","author":"SM Nelson","year":"2024","unstructured":"Nelson SM, Shaw M, Alrashid K, Anderson RA. Individualized dosing of follitropin delta affects live birth and safety in in vitro fertilization treatment: an individual participant data meta-analysis of randomized controlled trials. Fertil Steril. 2024;122:445\u201354. https:\/\/doi.org\/10.1016\/j.fertnstert.2024.05.143.","journal-title":"Fertil Steril"},{"key":"641_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2147\/IJWH.S193048","volume":"11","author":"W Xue","year":"2019","unstructured":"Xue W, Lloyd A, Falla E, Roeder C, Papsch R, B\u00fchler K. A cost-effectiveness evaluation of the originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany. Int J Womens Health. 2019;11:319\u201331. https:\/\/doi.org\/10.2147\/IJWH.S193048.","journal-title":"Int J Womens Health"},{"key":"641_CR18","doi-asserted-by":"publisher","first-page":"A403","DOI":"10.1016\/j.jval.2016.09.326","volume":"19","author":"M Sivignon","year":"2016","unstructured":"Sivignon M, Palencia R, Roze S. Cost minimisation analysis of follitropin delta versus follitropin alfa in assisted reproductive technologies (IVF\/ICSI) in the United Kingdom. Value Health. 2016;19:A403. https:\/\/doi.org\/10.1016\/j.jval.2016.09.326.","journal-title":"Value Health"},{"key":"641_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/13696998.2018.1551226","volume":"22","author":"M Grynberg","year":"2019","unstructured":"Grynberg M, Murphy C, Dor\u00e9 C, Fresneau L, Paillet S, Petrica N, et al. A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients undergoing a medically assisted reproduction program from a French perspective. J Med Econ. 2019;22:108\u201315. https:\/\/doi.org\/10.1080\/13696998.2018.1551226.","journal-title":"J Med Econ"},{"key":"641_CR20","unstructured":"ISPOR. Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation. ISPOR Int Soc Pharmacoeconomics Outcomes Res n.d. https:\/\/www.ispor.org\/heor-resources\/good-practices\/article\/principles-of-good-practice-for-decision-analytic-modeling-in-health-care-evaluation. Accessed 5 Feb 2026."},{"key":"641_CR21","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Choix m\u00e9thodologiques pour l\u2019\u00e9valuation \u00e9conomique \u00e0 la HAS. Haute Aut Sant\u00e9 n.d. https:\/\/www.has-sante.fr\/jcms\/r_1499251\/fr\/choix-methodologiques-pour-l-evaluation-economique-a-la-has. Accessed 3 Jan 2023."},{"key":"641_CR22","doi-asserted-by":"publisher","unstructured":"Suivi et orientation des femmes enceintes en fonction des situations \u00e0 risque identifi\u00e9es. Rev Sage-Femme. 2007;6:216\u20138. https:\/\/doi.org\/10.1016\/S1637-4088(07)79647-5.","DOI":"10.1016\/S1637-4088(07)79647-5"},{"key":"641_CR23","volume-title":"Antenatal care: routine care for the healthy pregnant woman","author":"National Collaborating Centre for Women\u2019s and Children\u2019s Health (Great Britain)","year":"2008","unstructured":"National Collaborating Centre for Women\u2019s and Children\u2019s Health (Great Britain), National Institute for Health and Clinical Excellence (Great Britain). Antenatal care: routine care for the healthy pregnant woman. London: RCOG Press; 2008."},{"key":"641_CR24","unstructured":"National Collaborating Centre for Women\u2019s and Children\u2019s Health (Great Britain) et National Institute for Health and Clinical Excellence (Great Britain) - 2008 - Antenatal care routine care for the healthy pregn.pdf n.d."},{"key":"641_CR25","unstructured":"Fertility problems: assessment and treatment 2017:51."},{"key":"641_CR26","unstructured":"The Management of Ovarian Hyperstimulation Syndrome - Royal College of Obstetricians & Gynaecologists, Green-top Guideline No.5, February 2016.pdf n.d."},{"key":"641_CR27","unstructured":"French National Health Insurance tariffs n.d. https:\/\/www.ameli.fr\/assure. Accessed 6 Nov 2024."},{"key":"641_CR28","unstructured":"ATIH. ATIH\u202f: Agence technique de l\u2019information sur l\u2019hospitalisation n.d. https:\/\/www.atih.sante.fr\/. Accessed 30 Oct 2024."},{"key":"641_CR29","unstructured":"INSEE. Indice des prix \u00e0 la consommation - Base 2015 - Ensemble des m\u00e9nages - France - Services de sant\u00e9 n.d. https:\/\/www.insee.fr\/fr\/statistiques\/serie\/001763845. Accessed 3 Jan 2023."},{"key":"641_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40258-017-0361-7","volume":"16","author":"P Barriere","year":"2018","unstructured":"Barriere P, Porcu-Buisson G, Hamamah S. Cost-effectiveness analysis of the gonadotropin treatments HP-hMG and rFSH for assisted reproductive technology in France: a Markov model analysis. Appl Health Econ Health Policy. 2018;16:65\u201377. https:\/\/doi.org\/10.1007\/s40258-017-0361-7.","journal-title":"Appl Health Econ Health Policy"},{"key":"641_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaf097.1034","volume":"40","author":"S Han","year":"2025","unstructured":"Han S, Yang R, Guan X, Carette J, Markert M, Liu C, et al. P-729 Cost-effectiveness of follitropin delta versus follitropin alfa for controlled ovarian stimulation for IVF\/ICSI in China. Hum Reprod. 2025;40:deaf097.1034. https:\/\/doi.org\/10.1093\/humrep\/deaf097.1034.","journal-title":"Hum Reprod"},{"key":"641_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejogrb.2023.12.011","volume":"293","author":"G Porcu-Buisson","year":"2024","unstructured":"Porcu-Buisson G, Maignien C, Swierkowski-Blanchard N, Rongi\u00e8res C, Ranisavljevic N, Oger P, et al. Prospective multicenter observational real-world study to assess the use, efficacy and safety profile of follitropin delta during IVF\/ICSI procedures (DELTA Study). Eur J Obstet Gynecol Reprod Biol. 2024;293:21\u20136. https:\/\/doi.org\/10.1016\/j.ejogrb.2023.12.011.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"641_CR33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s41669-023-00402-5","volume":"7","author":"C Skedgel","year":"2023","unstructured":"Skedgel C, Cubi-Molla P, Mott D, Gameiro S, Boivin J, Al-Janabi H, et al. Unmet parenthood goals, health-related quality of life and apparent irrationality: understanding the value of treatments for infertility. Pharmacoecon Open. 2023;7:337\u201344. https:\/\/doi.org\/10.1007\/s41669-023-00402-5.","journal-title":"Pharmacoecon Open"},{"key":"641_CR34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1093\/humrep\/den435","volume":"24","author":"M Connolly","year":"2009","unstructured":"Connolly M, Gallo F, Hoorens S, Ledger W. Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK. Hum Reprod Oxf Engl. 2009;24:626\u201332. https:\/\/doi.org\/10.1093\/humrep\/den435.","journal-title":"Hum Reprod Oxf Engl"},{"key":"641_CR35","doi-asserted-by":"publisher","unstructured":"\u00c1gh T, G\u00e1sp\u00e1r K, Nagy B, Lehmann M, Kal\u00f3 Z. The value of a child born in the European Union 2018. https:\/\/doi.org\/10.1556\/032.2018.68.2.6.","DOI":"10.1556\/032.2018.68.2.6"},{"key":"641_CR36","doi-asserted-by":"publisher","unstructured":"The European IVF Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE), Smeenk J, Wyns C, De Geyter C, Kupka M, Bergh C, et al. ART in Europe, 2019: results generated from European registries by ESHRE\u2020. Hum Reprod 2023;38:2321\u201338. https:\/\/doi.org\/10.1093\/humrep\/dead197.","DOI":"10.1093\/humrep\/dead197"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00641-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00641-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00641-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:57:16Z","timestamp":1779368236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00641-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["641"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00641-2","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been funded by Ferring Pharmaceuticals which is developing follitropin delta. The study sponsor participated in the study design, data collection, analysis and interpretation of data, writing of the manuscript, and in the decision to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Professor Samir Hamamah has received consultancy fees from Ferring Pharmaceuticals and Gedeon Richter, Marie Markert is an employee of Ferring Pharmaceuticals and Jeremy Carette and Henri Leleu have received consultancy fees.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable. The study only used previously published data that received ethical approval and consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable. The study only used previously published data that received ethical approval and consent to participate.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. The study only used previously published data that received ethical approval and consent to participate.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication (from patients\/participants)"}},{"value":"Ferring Pharmaceuticals A\/S will provide access to data upon reasonable request, via a secure portal, to researchers whose proposals meet the research criteria and other conditions, while ensuring compliance to patient privacy regulations. To gain access, data requestors must enter into a data access agreement with Ferring.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Transmission of the model may be provided upon request with appropriate authorization from Ferring.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the design and implementation of the research, to the analysis of the results, and to the writing and validation of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}